The Health Resources and Services Administration (HRSA) has approved a request from drug maker Eli Lilly to audit a rural, multi-site community health center regarding how it prevents duplicate discounts on 340B drugs reimbursed under Medicaid managed care. This approval is notable as it is the first time that either a HRSA or manufacturer 340B audit will look at Medicaid managed care drugs. (Previous audits around Medicaid have been limited to fee for service drugs.) The rationale behind HRSA’s change in policy is unclear.
